415 studies found for:    "Abdominal Neoplasms"
Show Display Options
Rank Status Study
1 Completed Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors
Conditions: Abdominal Neoplasms;   Pelvic Neoplasms
Intervention: Drug: Optison
2 Recruiting Nutritional Supplementation in Patients With no Signs of Malnutrition
Conditions: Primary Neoplasm;   Secondary Neoplasm;   Abdominal Neoplasm
Intervention: Dietary Supplement: Nutritional supplements
3 Completed
Has Results
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
Conditions: Abdominal Neoplasm;   Colonic Neoplasm;   Mesothelioma;   Peritoneal Neoplasm
Interventions: Procedure: Surgery;   Procedure: Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin;   Drug: Postoperative dwell with paclitaxel and 5-FU
4 Completed Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery
Condition: Abdominal Neoplasms
Interventions: Drug: enoxaparin;   Other: Physical prophylaxis
5 Completed Restricted Intravenous Fluid Regime Effects on Immunological Indicators of Elderly Patients Operated for Abdominal Cancer
Conditions: Surgery;   Perioperative Care;   Immunization;   Abdominal Neoplasms
Interventions: Behavioral: perioperative fluid management;   Behavioral: perioperative fluid treatment
6 Unknown  Comparison the Hemodynamics Effects Between Dexmedetomidine and Propofol in Major Abdominal Surgical Patients
Conditions: Abdominal Tumor;   Intestinal Obstruction;   Cirrhosis;   Intestinal Fistula;   Aneurism
Interventions: Drug: dexmedetomidine;   Drug: propofol
7 Recruiting TAP Versus Thoracic Epidural in Major Abdominal Resections
Conditions: Malignant Neoplasm of Abdomen;   Surgery
Interventions: Drug: Exparel 1.33% (20ml Volume);   Drug: 0.125% bupivicaine with 2 mcg/ml Fentanyl.
8 Recruiting Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours
Conditions: Cancer of Kidney and Renal Pelvis;   Cancer of Liver
Intervention: Drug: Dexmedetomidine
9 Completed Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
Conditions: Adenocarcinoma;   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms
Intervention: Procedure: MiCK Assay
10 Completed Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Bevacizumab;   Drug: Gemcitabine;   Drug: Carboplatin
11 Completed
Has Results
Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
Conditions: Peritoneal Neoplasms;   Intestinal Obstruction;   Carcinomatosis
Interventions: Drug: Octreotide LAR;   Drug: Octreotide (Immediate release);   Drug: methylprednisolone;   Drug: Placebo
12 Active, not recruiting Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: cisplatin;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
13 Unknown  Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Conditions: Anal Cancer;   Carcinoma of the Appendix;   Colorectal Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Gastric Cancer;   Gastrointestinal Carcinoid Tumor;   Liver Cancer;   Nausea and Vomiting;   Pancreatic Cancer;   Primary Peritoneal Cavity Cancer;   Small Intestine Cancer
Interventions: Drug: palonosetron hydrochloride;   Other: placebo
14 Completed
Has Results
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: tanespimycin
15 Completed Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy
Conditions: Ovarian Neoplasms;   Primary Peritoneal Cancer
Intervention: Drug: Pemetrexed
16 Completed Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Drug: cisplatin;   Drug: tirapazamine
17 Completed
Has Results
S9912 Combination Chemo in Stage III Ovarian Cancer,
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Drug: cisplatin;   Drug: liposomal doxorubicin;   Drug: paclitaxel
18 Completed Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
Conditions: Intestinal Obstruction;   Carcinoma;   Peritoneal Neoplasms
Interventions: Drug: Lanreotide (microparticle formulation);   Other: Placebo
19 Recruiting Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
Conditions: Relapsed Epithelial Ovarian Cancer;   Relapsed Primary Peritoneal Cancer;   Relapsed Fallopian Tube Cancer
Interventions: Drug: Birinapant;   Drug: Conatumumab
20 Completed Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Dietary Supplement: Early post-operative enteral feeding

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years